XML 60 R45.htm IDEA: XBRL DOCUMENT v3.25.2
Redeemable Convertible Preferred Stock and Stockholders' Deficit (Tables)
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Summary of Reserved for Issuance Upon the Potential Conversion or Exercise

The number of shares of Common Stock that have been reserved for issuance upon the potential conversion or exercise, as applicable, of the Company's securities as of December 31, 2024, is as follows:

 

Outstanding options to purchase Common Stock

 

 

265,772

 

Restricted Stock Units

 

 

104,500

 

Warrants to purchase Common Stock

 

 

767,697

 

Shares of Common Stock issued upon the exercise of Public Warrants

 

 

750,383

 

Earn-Out shares

 

 

360,000

 

Convertible Notes

 

 

2,532,336

 

Total

 

 

4,780,688

 

Summary of Warrants to Purchase the Classes of Preferred Stock and Common Stock Outstanding As of December 31, 2024, there were 14,589 Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified.

In connection with the Public Offering and Private Placement, we issued the Public Offering Warrants and Private Placement Warrants. As of December 31, 2024, there were 662,701 Public Offering Warrants and 90,407 Private Placement Warrants outstanding to purchase Common Stock.

 

December 31, 2024

 

Issuance Date

 

Remaining
Contractual Term
(in years)

 

 

Underlying Equity Instrument

 

Balance Sheet
Classification

 

Shares Issuable
Upon Exercise
of Warrant

 

 

Weighted
Average Exercise
Price

 

12/1/2014

 

 

-0.1

 

 

Common stock

 

Equity

 

 

209

 

 

$

61.00

 

3/30/2021

 

 

6.2

 

 

Common stock

 

Liability

 

 

5,203

 

 

 

168.25

 

9/15/2022

 

 

7.7

 

 

Common stock

 

Liability

 

 

1,810

 

 

 

303.50

 

6/4/2022

 

 

7.4

 

 

Common stock

 

Liability

 

 

1,810

 

 

 

303.50

 

1/17/2017

 

 

2.0

 

 

Common stock

 

Equity

 

 

2,934

 

 

 

0.50

 

8/3/2017

 

 

2.6

 

 

Common stock

 

Equity

 

 

392

 

 

 

28.25

 

9/8/2017

 

 

2.7

 

 

Common stock

 

Liability

 

 

1,151

 

 

 

26.25

 

6/19/2018

 

 

3.5

 

 

Common stock

 

Liability

 

 

720

 

 

 

26.25

 

6/25/2019

 

 

4.5

 

 

Common stock

 

Liability

 

 

360

 

 

 

26.25

 

7/1/2024

 

 

4.5

 

 

Common stock

 

Liability

 

 

753,108

 

 

 

30.00

 

 

 

 

 

 

 

 

 

 

767,697

 

 

 

 

 

December 31, 2023

 

Issuance Date

 

Remaining
Contractual Term
(in years)

 

 

Underlying Equity Instrument

 

Balance Sheet
Classification

 

Shares Issuable
Upon Exercise
of Warrant

 

 

Weighted
Average Exercise
Price

 

12/1/2014

 

 

0.9

 

 

Common stock

 

Equity

 

 

1,771

 

 

$

61.00

 

3/30/2021

 

 

7.2

 

 

Common stock

 

Liability

 

 

5,203

 

 

 

168.25

 

9/15/2022

 

 

8.7

 

 

Common stock

 

Liability

 

 

1,810

 

 

 

303.50

 

6/4/2022

 

 

8.4

 

 

Common stock

 

Liability

 

 

1,810

 

 

 

303.50

 

1/17/2017

 

 

3.0

 

 

Common stock

 

Equity

 

 

2,934

 

 

 

0.50

 

8/3/2017

 

 

3.6

 

 

Common stock

 

Equity

 

 

392

 

 

 

28.25

 

9/8/2017

 

 

3.7

 

 

Common stock

 

Liability

 

 

1,151

 

 

 

26.25

 

6/19/2018

 

 

4.5

 

 

Common stock

 

Liability

 

 

720

 

 

 

26.25

 

6/25/2019

 

 

5.5

 

 

Common stock

 

Liability

 

 

360

 

 

 

26.25

 

 

 

 

 

 

 

 

 

 

16,151